Stock Events

Relay Therapeutics 

$10
22
-$0.57-5.39% Friday 21:00

Statistics

Day High
10.89
Day Low
9.36
52W High
19.54
52W Low
5.95
Volume
2,493,376
Avg. Volume
1,058,706
Mkt Cap
1.27B
P/E Ratio
-3.73
Dividend Yield
-
Dividend
-

Earnings

22FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.83
-0.73
-0.64
-0.54
Expected EPS
-0.73
Actual EPS
-0.67

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RLAY. It's not an investment recommendation.

Analyst Ratings

23.5$Average Price Target
The highest estimate is $30.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Employees
163
Country
US
ISIN
US75943R1023

Listings